A comprehensive umbrella meta-analysis evaluates efficacy and multisystem safety of adding immune checkpoint inhibitors to chemotherapy for advanced triple-negative breast cancer.
Key Takeaways
- Characterized by the absence of estrogen receptor (ER)
- Globally, the incidence of TNBC has shown a steady increase ( 3 )
- This subgroup presents considerable therapeutic challenges and is characterized by a generally poor prognosis ( 4 , 5 )